Cancer Research and Treatment

Case Report

Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy: Hee Yeon Seo, Eui Bae Kim, Jee Won Kim, Bong Kyoung Shin, Seok Jin Kim, Byung Soo Kim; Cancer Res Treat. 2009;41(2):104-107. Published online June 30, 2009; DOI: https://doi.org/10.4143/crt.2009.41.2.104

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder. Although MCD pathogenesis is unclear, studies have suggested that human herpesvirus 8 (HHV-8) may be associated with the disorder. Recent reports have identified MCD cases without viral infection. A 43-year-old woman presented to our hospital for fever and myalgia of 6 months' duration. The complete blood count revealed an elevated leukocyte count (15.1×10³/µL) and a decreased hemoglobin level of 10.0 g/dL. The C-reactive protein level was elevated at 276.5 mg/L. Thoracic computed tomography (CT) scans revealed bilateral axillary lymphadenopathy. There was no evidence of HHV-8, human immunodeficiency virus (HIV), or Mycobacterium infection. Histologic evaluation of a lymph node biopsy from the left axilla yielded a diagnosis of MCD. Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. The patient's fever and lymphadenopathy resolved after the course of chemotherapy. She has been in complete remission for 24 months at this writing. As previously reported, this case report suggests that MCD can develop without viral infection. CHOP chemotherapy may be an effective treatment option for newly diagnosed MCD patients.

Citations

Citations to this article as recorded by

A diagnostic and therapeutically challenging presentation of unicentric mesenteric Castleman disease: A case report
Lixin Hua, Zhibin Yin, Ruirui Yang
Experimental and Therapeutic Medicine.2025; 29(4): 1. CrossRef
Autoreactive Antibodies Associated with Castleman Disease Triad
Jacqueline A. Turner, Ali Hakimi, Hannah Lee, Jeffrey T. Schowinsky, Jeffrey M. Sippel, Bradford J. Siegele, Raul M. Torres, William A. Robinson, Necil Kütükçüler
Case Reports in Immunology.2024; 2024: 1. CrossRef
Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center
Ashok Singh, Suvendu Purkait, Saumyaranjan Mallick, Prashant Ramteke, Chandan Krushna Das, Ajay Gogia, Maher Chand Sharma, Lalit Kumar
Indian Journal of Hematology and Blood Transfusion.2020; 36(2): 254. CrossRef
Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman’s disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately
Xuan Lan, Zhaoming Li, Mingzhi Zhang
Journal of Cancer Research and Clinical Oncology.2018; 144(7): 1265. CrossRef
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease
Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young
Blood.2017; 129(12): 1658. CrossRef
Clinical management of HIV-associated hematologic malignancies
Chia-Ching J. Wang, Lawrence D. Kaplan
Expert Review of Hematology.2016; 9(4): 361. CrossRef
Practical Management of Castleman's Disease
Musa Fares Alzahrani, Mansoor Radwi, Heather A. Leitch
Acta Haematologica.2016; 136(1): 16. CrossRef
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome
Musa Alzahrani, Mark C. Hull, Christopher Sherlock, Deborah Griswold, Chantal S. Leger, Heather A. Leitch
Leukemia & Lymphoma.2015; 56(5): 1246. CrossRef
An unusual presentation: A case of Multicentric Castleman's disease presenting as bilateral pleural effusions
Priya K. Simoes, Narender Annapureddy, Vaidehi Avadhani, Gangajal Kasnia, Girish N. Nadkarni
HIV & AIDS Review.2015; 14(3): 84. CrossRef
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance
Lucie M. Turcotte, Colleen K. Correll, Robyn C. Reed, Christopher L. Moertel
Pediatric Blood & Cancer.2014; 61(4): 737. CrossRef
Diagnosis and Management of Castleman Disease
Jacob D. Soumerai, Aliyah R. Sohani, Jeremy S. Abramson
Cancer Control.2014; 21(4): 266. CrossRef
Multicentric Castleman’s Disease: A Challenging Diagnosis
Györgyi Műzes, Ferenc Sipos, Judit Csomor, Lídia Sréter
Pathology & Oncology Research.2013; 19(3): 345. CrossRef
Clinical Features and Outcomes of Head and Neck Castleman Disease
Yan-Feng Chen, Wei-Dong Zhang, Chuan-Zheng Sun, Dian OuYang, Wen-Kuan Chen, Rong-Zhen Luo, Ming-Wei Wu
Journal of Oral and Maxillofacial Surgery.2012; 70(10): 2466. CrossRef
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
Hazem E. El-Osta, Razelle Kurzrock
The Oncologist.2011; 16(4): 497. CrossRef

11,545 View
64 Download
14 Crossref

Original Articles

Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer: Dae Sik Kim, Jae Sook Sung, Eun Soon Shin, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Yong Park, Eui Bae Kim, Seh Jong Park, Yeul Hong Kim; Cancer Res Treat. 2008;40(4):190-196. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.190

Abstract PDF PubReader ePub

Purpose

The expression of the PIM-1 gene, which is a proto-oncogene that encodes a serine/threonine kinase, is associated with multiple cellular functions such as proliferation, differentiation, apoptosis and tumorigenesis. In particular, several studies have reported that the PIM-1 gene is associated with the development of lymphoma, leukemia and prostate cancer. Therefore, this study was conducted to evaluate the association between the single nucleotide polymorphisms in the PIM-1 gene and the risk of lung cancer occurrence in the Korean population.

Materials and Methods

To evaluate the role of the PIM-1 gene in the development of lung cancer, the genotypes of the PIM-1 gene were determined in 408 lung cancer patients and 410 normal subjects.

Results

We found that the T-C-T-C haplotypes of the PIM-1 gene (-1196 T>C, IVS4 +55 T>C, IVS4 +1416 T>A and +3684 C>A) were associated with an increased risk of lung cancer [adjusted odds ratio (aOR): 3.98; 95% CI: 1.24~12.75, p-value: 0.020]. In particular, these haplotypes showed an increased risk of lung cancer in males (aOR: 5.67; 95% CI: 1.32~24.30, p-value: 0.019) and smokers (aOR: 7.82; 95% CI: 1.75~34.98, p-value: 0.007).

Conclusions

The present results suggest that the T-C-T-C haplotype of the PIM-1 gene could influence the risk of developing smoking-related lung cancer in the Korean population. Additional functional studies with an larger sample sized analysis are warranted to reconfirm our findings.

Citations

Citations to this article as recorded by

A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target
Ajaya Kumar Rout, Budheswar Dehury, Satya Narayan Parida, Sushree Swati Rout, Rajkumar Jena, Neha Kaushik, Nagendra Kumar Kaushik, Sukanta Kumar Pradhan, Chita Ranjan Sahoo, Ashok Kumar Singh, Meenakshi Arya, Bijay Kumar Behera
International Journal of Biological Macromolecules.2024; 270: 132030. CrossRef
Impact of Pim1 mutations on the survival outcomes of patients with breast cancer: Insights from a clinical study
Syed Sultan Beevi, Kavitha Anbrasu, Vinod Kumar Verma, Nagesh Kishan Panchal, Krishna Kiran Kannepalli, Raghu Ram Pillarisetti, Sailaja Madigubba, Jyotsana Dwivedi, Neha Damodar, Radhika Chowdary Darapuneni
Human Gene.2024; 40: 201295. CrossRef
HCG11 inhibits salivary adenoid cystic carcinoma by upregulating EphA2 via binding to miR-1297
Shujuan Yan, Meng Wang
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(2): 257. CrossRef
Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque, Md Imtaiyaz Hassan
Biochimica et Biophysica Acta (BBA) - General Subjects.2021; 1865(11): 129995. CrossRef
Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)
Jiajie Xu, Xin Zhu, Qingling Li, Chao Chen, Zhenying Guo, Zhuo Tan, Chuanming Zheng, Minghua Ge
Cancer Cell International.2018;[Epub] CrossRef
PIM Kinase as an Executional Target in Cancer
Xinning Zhang, Mengqiu Song, Joydeb Kumar Kundu, Mee-Hyun Lee, Zhen-Zhen Liu
Journal of Cancer Prevention.2018; 23(3): 109. CrossRef
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372
Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu, Qidi Zheng, Hu Pu, Xin Gui, Tianming Li, Dongdong Lu
Oncotarget.2017; 8(30): 49093. CrossRef
Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)
Yi Jin, Da-yue Tong, Lu-ying Tang, Jian-ning Chen, Jing Zhou, Zhi-ying Feng, Chun-kui Shao
Chinese Journal of Cancer Research.2012; 24(2): 103. CrossRef
Overexpression of Osteopontin, αvβ3 and Pim-1 Associated with Prognostically Important Clinicopathologic Variables in Non-Small Cell Lung Cancer
Yi Jin, Da-yue Tong, Jian-ning Chen, Zhi-ying Feng, Jian-yong Yang, Chun-kui Shao, Jia-ping Li, Rossella Rota
PLoS ONE.2012; 7(10): e48575. CrossRef
No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population
Jae-Sook Sung, Kyong-Hwa Park, Seung-Tae Kim, Jae-Hong Seo, Sang-Won Shin, Jun-Suk Kim, Yeul-Hong Kim
Genomics & Informatics.2010; 8(4): 194. CrossRef

13,262 View
85 Download
10 Crossref

Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer: Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung; Cancer Res Treat. 2008;40(4):178-183. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.178

Abstract PDF PubReader ePub

Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by

Bridging the gap between tumor evolution and clonality diagnostics in multiple lung carcinomas
Jurriaan Janssen, Michael Allgäuer, Bauke Ylstra, Swip Draijer, Yongsoo Kim, Jan Budczies, Daniel Kazdal, Albrecht Stenzinger, Martina Kirchner, Teodora Radonic
Seminars in Cancer Biology.2026; 122: 1. CrossRef
Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer
Gabriela Rahnea-Nita, Alexandru Nechifor, Mihai-Teodor Georgescu, Dorel Firescu, Adrian-Cornel Maier, Radu-Valeriu Toma, Valentin Titus Grigorean, Liliana-Florina Andronache, Roxana-Andreea Rahnea-Nita, Ionut Simion Coman, Laura-Florentina Rebegea
Journal of Clinical Medicine.2025; 14(10): 3299. CrossRef
African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
Head & Neck.2022; 44(10): 2069. CrossRef
Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
World Journal of Nuclear Medicine.2021; 20(02): 164. CrossRef
Modern Radiology in the Management of Head and Neck Cancer
G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
Clinical Oncology.2016; 28(7): 440. CrossRef
Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
Journal of Craniofacial Surgery.2011; 22(1): 348. CrossRef

13,097 View
72 Download
6 Crossref

The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer: Yong Park, Jee Won Kim, Dae Sik Kim, Eui Bae Kim, Se Jong Park, Jin Yong Park, Woo Suk Choi, Jong Gyu Song, Hee Yun Seo, Sang Cheul Oh, Byung Soo Kim, Jong Jae Park, Yeul Hong Kim, Jun Suk Kim; Cancer Res Treat. 2008;40(3):127-132. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.127

Abstract PDF PubReader ePub

Purpose

Bone Morphogenetic Proteins (BMPs) are members of the TGF-β superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer.

Materials and Methods

Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively.

Results

No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021).

Conclusions

BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.

Citations

Citations to this article as recorded by

Identification and validation of biomarkers in gastric cancer-associated membranous nephropathy: Insights from comprehensive bioinformatics analysis and machine learning
Qianqian Xu, Yue Yang, Cong Zhang, Min Tan, Jiayi Li, Wenge Li
Frontiers in Immunology.2025;[Epub] CrossRef
Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study
Lazar Chisavu, Viviana Mihaela Ivan, Adelina Mihaescu, Flavia Chisavu, Oana Schiller, Luciana Marc, Flaviu Bob, Adalbert Schiller
Diagnostics.2024; 14(6): 664. CrossRef
Duality of bone morphogenetic proteins in cancer: A comprehensive analysis
Tanu Sharma, Anmol Kapoor, Chandi C. Mandal
Journal of Cellular Physiology.2022; 237(8): 3127. CrossRef
BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer
Zilu Chen, Liyue Yuan, Xiaopeng Li, Junhui Yu, Zhengshui Xu
Cell Cycle.2022; 21(21): 2298. CrossRef
Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour
Alejandro Álvarez-Artime, Belén García-Soler, Rosa María Sainz, Juan Carlos Mayo
International Journal of Molecular Sciences.2021; 22(11): 5560. CrossRef
Magnesium ions regulate mesenchymal stem cells population and osteogenic differentiation: A fuzzy agent-based modeling approach
Jalil Nourisa, Berit Zeller-Plumhoff, Heike Helmholz, Bérengère Luthringer-Feyerabend, Vladimir Ivannikov, Regine Willumeit-Römer
Computational and Structural Biotechnology Journal.2021; 19: 4110. CrossRef
BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
Yongchun Zhang, Jianwen Que
Annual Review of Physiology.2020; 82(1): 251. CrossRef
Relaxin enhances bone regeneration with BMP‐2‐loaded hydroxyapatite microspheres
Sahitya Injamuri, Mohamed N. Rahaman, Youqu Shen, Yue‐Wern Huang
Journal of Biomedical Materials Research Part A.2020; 108(5): 1231. CrossRef
Annatto-Derived Tocotrienol Promotes Mineralization of MC3T3-E1 Cells by Enhancing BMP-2 Protein Expression via Inhibiting RhoA Activation and HMG-CoA Reductase Gene Expression

Wan Nuraini Wan Hasan, Kok-Yong Chin, Norzana Abd Ghafar, Ima Nirwana Soelaiman
Drug Design, Development and Therapy.2020; Volume 14: 969. CrossRef
Detection of circulating BMP5 as a risk factor for Barrett’s esophagus
Ana C. P. Correia, Silvia Calpe, Nahid Mostafavi, Sanne Johanna Maria Hoefnagel, Maria del Carmen Sancho-Serra, Patricia S. de Koning, Kausilia K. Krishnadath
Scientific Reports.2020;[Epub] CrossRef
The Dual Role of Bone Morphogenetic Proteins in Cancer
Duc-Hiep Bach, Hyen Joo Park, Sang Kook Lee
Molecular Therapy - Oncolytics.2018; 8: 1. CrossRef
Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
Tobias Sinnberg, Heike Niessner, Mitch P. Levesque, Christoph Dettweiler, Claus Garbe, Christian Busch
Biology Open.2018;[Epub] CrossRef
Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis
Bum Sik Tae, Seok Cho, Hyun Cheol Kim, Cheol Hwan Kim, Seok Ho Kang, Jeong Gu Lee, Je Jong Kim, Hong Seok Park, Jun Cheon, Mi Mi Oh, Sung Gu Kang
Scientific Reports.2018;[Epub] CrossRef
Computational model of mesenchymal migration in 3D under chemotaxis
F. O. Ribeiro, M. J. Gómez-Benito, J. Folgado, P. R. Fernandes, J. M. García-Aznar
Computer Methods in Biomechanics and Biomedical Engineering.2017; 20(1): 59. CrossRef
Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
Haijun Tian, Jie Zhao, Elsa J. Brochmann, Jeffrey C. Wang, Samuel S. Murray
Cytokine & Growth Factor Reviews.2017; 34: 73. CrossRef
BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells
Min Hu, Facai Cui, Fengzhen Liu, Jinlin Wang, Xiaoxia Wei, Yi Li
International Journal of Oncology.2017; 50(1): 193. CrossRef
Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
Jian Sun, Xuan Liu, Hong Gao, Long Zhang, Qing Ji, Ziyuan Wang, Lihong Zhou, Yan Wang, Hua Sui, Zhongze Fan, Qi Li
Oncotarget.2017; 8(7): 11489. CrossRef
BMP10 inhibited the growth and migration of gastric cancer cells
Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu
Tumor Biology.2016; 37(3): 3025. CrossRef
How does the pathophysiological context influence delivery of bone growth factors?
Xiaohua Yu, Darilis Suárez-González, Andrew S. Khalil, William L. Murphy
Advanced Drug Delivery Reviews.2015; 84: 68. CrossRef
Inactivation of the Phosphatidylinositol 3‐Kinase/Akt Pathway is Involved in BMP9‐mediated Tumor‐suppressive Effects in Gastric Cancer Cells
Liang Duan, Liwei Ye, Rui Wu, Haiyan Wang, Xueru Li, Huan Li, Shimei Yuan, He Zha, Hui Sun, Yunyuan Zhang, Xian Chen, Yan Zhang, Lan Zhou
Journal of Cellular Biochemistry.2015; 116(6): 1080. CrossRef
Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
Yun-Jung Choi, Patrick N. Ingram, Kun Yang, Lan Coffman, Mangala Iyengar, Shoumei Bai, Dafydd G. Thomas, Euisik Yoon, Ronald J. Buckanovich
Proceedings of the National Academy of Sciences.2015;[Epub] CrossRef
Association Between BMP-2 and Carcinogenicity
Branko Skovrlj, Steven M. Koehler, Paul A. Anderson, Sheeraz A. Qureshi, Andrew C. Hecht, James C. Iatridis, Samuel K. Cho
Spine.2015; 40(23): 1862. CrossRef
In silico Mechano-Chemical Model of Bone Healing for the Regeneration of Critical Defects: The Effect of BMP-2
Frederico O. Ribeiro, María José Gómez-Benito, João Folgado, Paulo R. Fernandes, José Manuel García-Aznar, Masaya Yamamoto
PLOS ONE.2015; 10(6): e0127722. CrossRef
Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers
DAN FENG, XIAOFEI YE, ZHENXIN ZHU, ZIRAN WEI, QINGPING CAI, YAJIE WANG
Molecular Medicine Reports.2015; 11(1): 386. CrossRef
Gastric stem cells and gastric cancer stem cells
Myoung-Eun Han, Sae-Ock Oh
Anatomy & Cell Biology.2013; 46(1): 8. CrossRef
Cancer stem cells: the ‘heartbeat’ of gastric cancer
Guihua Xu, Jie Shen, Xiaohui Ou Yang, Masakiyo Sasahara, Xiulan Su
Journal of Gastroenterology.2013; 48(7): 781. CrossRef
Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients
Zheng-Hua Fei, Cheng-Yun Yao, Xiao-Lei Yang, Xin-En Huang, Sheng-Lin Ma
Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5293. CrossRef
P‐glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal‐induced cell shape in chimpanzee left cerebrum by systems‐theoretical analysis
Hong Lin, Lin Wang, Minghu Jiang, Juxiang Huang, Lianxiu Qi
Cell Biochemistry and Function.2012; 30(7): 582. CrossRef
Bone–vasculature interactions in the mandible: Is bone an angiogenic tissue?
E.M. Dietrich, K. Antoniades
Medical Hypotheses.2012; 79(5): 582. CrossRef
Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients
Elísio Costa, Joana Coimbra, Cristina Catarino, Sandra Ribeiro, Flávio Reis, Henrique Nascimento, João Fernandes, Vasco Miranda, Maria do Sameiro Faria, Luís Belo, Alice Santos-Silva
Renal Failure.2012; 34(10): 1355. CrossRef
Bone Morphogenetic Protein-4-induced Epithelial-Mesenchymal Transition and Invasiveness Through Smad1-mediated Signal Pathway in Squamous Cell Carcinoma of the Head and Neck
Ting Xu, Chang-yun Yu, Jin-jie Sun, Yong Liu, Xing-wei Wang, Lei-ming Pi, Yong-quan Tian, Xin Zhang
Archives of Medical Research.2011; 42(2): 128. CrossRef
Bone Morphogenetic Protein-2 and -4 Play Tumor Suppressive Roles in Human Diffuse-Type Gastric Carcinoma
Yo-taro Shirai, Shogo Ehata, Masakazu Yashiro, Kazuyoshi Yanagihara, Kosei Hirakawa, Kohei Miyazono
The American Journal of Pathology.2011; 179(6): 2920. CrossRef
Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression
Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo
Experimental Cell Research.2011; 317(12): 1746. CrossRef
Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma
Ulrike Maegdefrau, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff
Laboratory Investigation.2011; 91(11): 1615. CrossRef
Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy
JIN-SOON SUH, WON-HO HAHN, JONG SEOK LEE, HAE JEONG PARK, MI-JA KIM, SUNG WOOK KANG, JOO-HO CHUNG, BYOUNG-SOO CHO
Experimental and Therapeutic Medicine.2011; 2(2): 337. CrossRef
Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh
Medical Oncology.2010; 27(4): 1192. CrossRef
The Yin and Yang of bone morphogenetic proteins in cancer
Ashok Singh, Rebecca J. Morris
Cytokine & Growth Factor Reviews.2010; 21(4): 299. CrossRef
BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
Myoung Hee Kang, Jun Suk Kim, Ji Eun Seo, Sang Cheul Oh, Young A. Yoo
Experimental Cell Research.2010; 316(1): 24. CrossRef

14,371 View
77 Download
38 Crossref

Case Report

Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy: Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim; Cancer Res Treat. 2008;40(1):36-38. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.36

Abstract PDF PubReader ePub

Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.

Citations

Citations to this article as recorded by

Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
Rui Lu, Meng Zhang, Zi-Han Liu, Miao Hao, Yan Tian, Mei Li, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Zi-Cheng Jiang, Xue-Mei Li, Guang-Hua Xu, Ya-Ping Li, Shuang-Suo Dang
World Journal of Gastroenterology.2024; 30(44): 4725. CrossRef
Very late-onset hepatitis B reactivation following chemoimmunotherapy
Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
Leukemia & Lymphoma.2022; 63(4): 991. CrossRef
Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang
Hematology.2021; 26(1): 956. CrossRef
Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama
Endocrinology, Diabetes & Metabolism.2019;[Epub] CrossRef
Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano
Leukemia & Lymphoma.2015; 56(4): 1160. CrossRef
Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
Jesse Civan, Hie Won Hann
Expert Opinion on Drug Safety.2015; 14(6): 865. CrossRef
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
Mauro Viganò, Giampaolo Mangia, Pietro Lampertico
Expert Opinion on Biological Therapy.2014; 14(7): 1019. CrossRef
A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park
Kosin Medical Journal.2014; 29(2): 161. CrossRef
Occult Hepatitis B Virus Infection: Transmission and Reactivation
Sang Hee Song, Seong Gyu Hwang
The Korean Journal of Gastroenterology.2013; 62(3): 148. CrossRef
Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim
Korean Journal of Medicine.2013; 85(6): 598. CrossRef
Occult Hepatitis B: Clinical Viewpoint and Management
Mehdi Zobeiri
Hepatitis Research and Treatment.2013; 2013: 1. CrossRef
Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi
Journal of Clinical Microbiology.2013; 51(7): 2238. CrossRef
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami
Journal of Gastroenterology.2011; 46(1): 9. CrossRef
Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi
The Korean Journal of Gastroenterology.2010; 55(4): 266. CrossRef
Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino
Medical Oncology.2010; 27(3): 912. CrossRef

16,618 View
91 Download
15 Crossref

First
Prev
Page of 1
Next
Last

Search